IVERIC bio, Inc.
ISEEDelisted- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001410939
IVERIC bio, Inc. was delisted in 2023; its insiders filed their last Form 4 on Jul 13, 2023; 256 institutions reported holding it in 13F filings for Q2 2023, worth $5.33B in total; Soros Fund Management was the only superinvestor holding it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 256
- Q2 2023, +33 vs. previous quarter
- 13F value
- $5.33B
- Reported value at the end of Q2 2023
- Superinvestors holding
- 1
- At the end of Q2 2023
Superinvestors holding ISEE, Q2 2023
1 superinvestor reports holding IVERIC bio, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Soros Fund Management
George Soros
1.5%
IVERIC bio, Inc.'s share of the portfolio
- Shares
- 1,700,001
- Value
- $66.9M
Latest insider trades
Open-market purchases and sales by IVERIC bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2023 (view filing) | Jul 3 | 3 days | Westby KeithSVP, Chief Operating Officer | SSale | −20.0K | $39.45 | −$789.0K | −33.5%39.7K after | 10b5-1 |
| Jun 6, 2023 (view filing) | Jun 2 | 4 days | Westby KeithSVP, Chief Operating Officer | SSale | −20.0K | $37.87 | −$757.4K | −33.5%39.7K after | 10b5-1 |
| May 3, 2023 (view filing) | May 1-2 | 2 days | Westby KeithSVP, Chief Operating Officer | SSale | −40.0K | $37.47 | −$1.50M | −50.2%39.7K after | 3 lots10b5-1 |
| May 3, 2023 (view filing) | May 1 | 2 days | Carroll David FrancisSVP, Chief Financial Officer | SSale | −63.5K | $37.04 | −$2.35M | −48.1%68.5K after | 10b5-1 |
| Apr 25, 2023 (view filing) | Apr 21-24 | 4 days | Carroll David FrancisSVP, Chief Financial Officer | SSale | −50.0K | $30.20 | −$1.51M | −42.2%68.5K after | 2 lots10b5-1 |
| Apr 25, 2023 (view filing) | Apr 21-24 | 4 days | Westby KeithSVP, Chief Operating Officer | SSale | −20.0K | $30.07 | −$601.3K | −33.5%39.7K after | 2 lots10b5-1 |
| Apr 5, 2023 (view filing) | Apr 3 | 2 days | Westby KeithSVP, Chief Operating Officer | SSale | −40.0K | $26.70 | −$1.07M | −50.2%39.7K after | 2 lots10b5-1 |
| Mar 6, 2023 (view filing) | Mar 2 | 4 days | Westby KeithSVP, Chief Operating Officer | SSale | −20.0K | $23.93 | −$478.6K | −33.5%39.7K after | 2 lots |
| Feb 22, 2023 (view filing) | Feb 17 | 5 days | Westby KeithSVP, Chief Operating Officer | SSale | −15.0K | $25.05 | −$375.8K | −24.4%46.4K after | 2 lots |
| Feb 3, 2023 (view filing) | Feb 1-2 | 2 days | Westby KeithSVP, Chief Operating Officer | SSale | −40.0K | $23.43 | −$937.0K | −46.3%46.4K after | 2 lots |
Top 10 13F holders, Q2 2023
The largest institutional positions in IVERIC bio, Inc. at the end of Q2 2023; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 13,678,616 | $538.1M | 0.01% | +17,227+0.1% | Added |
| BlackRock Inc. | 10,789,526 | $424.5M | 0.01% | +661,051+6.5% | Added |
| Avoro Capital Advisors LLC | 8,050,000 | $316.7M | 4.30% | +1,250,000+18.4% | Added |
| UBS Oconnor LLC | 5,850,120 | $230.1M | 4.87% | +5,850,120 | New |
| Beryl Capital Management LLC | 5,339,518 | $210.1M | 64.81% | +5,339,518 | New |
| State Street Corp | 4,677,893 | $184.0M | 0.01% | −946,285−16.8% | Reduced |
| Goldman Sachs Group Inc | 4,222,280 | $166.1M | 0.04% | +3,225,818+323.7% | Added |
| Millennium Management LLC | 3,959,870 | $155.8M | 0.17% | +2,719,573+219.3% | Added |
| Deutsche Bank AG | 3,192,342 | $125.6M | 0.07% | +1,910,414+149.0% | Added |
| TIG Advisors, LLC | 2,904,364 | $114.3M | 6.88% | +2,904,364 | New |